NecstGen, a center of excellence in Cell and Gene Therapy development and manufacturing, announced on May 6th a partnership with Astraveus to evaluate the Lakhesys™ Benchtop Cell Factory, a novel microfluidic manufacturing platform designed to transform the production of CAR-T therapies.
NecstGen (based in Leiden, The Netherlands) will use Astraveus’ Lakhesys™ system to explore its potential in delivering a scalable, cost-effective alternative to conventional CAR-T manufacturing processes. The project is set to demonstrate the ability of benchtop, closed-system automation to address key bottlenecks in Cell Therapy production. Additionally, NecstGen will produce Lentiviral vector for Astraveus’ internal research and development needs.
Astraveus (based in Paris, France) recently showcased the first complete end-to-end CAR-T manufacturing run on the Lakhesys™ platform and is now starting external testing of its new manufacturing platform with partners. With its microfluidic core, the system offers a significant reduction in footprint, resources, and hands-on processing time.
More information: NecstGen / Astraveus
Bron: NecstGen, Astraveus